TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31740862

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.4 MAC with propofol 1mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane at 1.2 MAC alone
Number of subjects: 50
Study: 28694471

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2% doxycycline solution
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 5% Proanthocyanidin (PR)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 4
Study: 25867446

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy guided self-help (CBTgsh)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL)
Number of subjects: 205

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy guided self-help (CBTgsh) and Interpersonal psychotherapy (IPT)
Number of subjects: 205
Study: 23657091

Group type: EXPERIMENTAL
Intervention: Mobile whole body MRI measurements at intervals of 800 km during the ultramarathon
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of body composition between finishers and non-finishers
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correlation of visceral adipose tissue (VAT) with prerace training volume and intensity
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Assessment of body composition changes and performance relationship
Number of subjects: 22
Study: 20196109

Group type: EXPERIMENTAL
Intervention: DBT‐AF (appetite focused dialectical behavior therapy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 32
Study: 19708562

Group type: EXPERIMENTAL
Intervention: Transcranial electrotherapy using a TRANSAIR‐02 apparatus (combined with traditional treatment)
Number of subjects: 100
Study: 18044688

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Salmeterol 50 microg bid
Number of subjects: 1186
Study: 14571451

Group type: EXPERIMENTAL
Intervention: Fluoride gel treatment (EF group)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Fluoride gel treatment followed by argon laser irradiation (EFL group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No treatment (E group)
Number of subjects: 98
Study: 10594469

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Doxazosin standard (1 mg day-1 titrated to higher dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS with high-fat meal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg and 8 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS once daily for 7 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 100
Study: 8918276

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 6595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study: 1746667

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 450
Study: 6762670

Group type: EXPERIMENTAL
Intervention: Manipulation of the cervical spine with an amnesic dose of diazepam
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group received diazepam but no manipulation
Number of subjects: 21
Study: 6421359

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (10 micrograms) given at 0, 1, and 2 months of age
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (10 micrograms) given at 3, 4, and 5 months of age
Number of subjects: 20
Study: 30348353

Group type: EXPERIMENTAL
Intervention: Adult spinal deformity surgery
Number of subjects: 153
Study: 27276421

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) 33 mg kg(‐1) single oral dose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Deferiprone 3‐O‐glucuronide (DFP‐G)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Safety monitoring of DFP
Number of subjects: 32
Study: 24134074

Group type: EXPERIMENTAL
Intervention: 25% dextrose (D25)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 10% dextrose (D10)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 150
Study: 23383461

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (true acupuncture needles), treated once every other day for 12 sessions
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (true acupuncture needles)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo acupuncture (placebo acupuncture needles)
Number of subjects: 118
Study: 20655809

Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) for 30 minutes
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) for 60 minutes
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin patch) for 90 minutes
Number of subjects: 299

Group type: COMPARATOR
Intervention: Pooled control group (0.04% capsaicin patch)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: NGX-4010 (30 minutes)
Number of subjects: 299
Study: 18841250

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 15901456

Group type: EXPERIMENTAL
Intervention: G1.2-G2.2 media
Number of subjects: 599

Group type: COMPARATOR
Intervention: GIII series sequential media
Number of subjects: 599
Study: 12525796

Group type: EXPERIMENTAL
Intervention: PYC (200 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 10378920

Group type: EXPERIMENTAL
Intervention: T1: initial speed of 6 km x h(‐1) followed by increments of 0.6 km x h(‐1) every 60 s
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: T2: initial speed 5.6 km x h(‐1) followed by increments of 0.2 km x h(‐1) every 20 s
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: T3: similar to T2, in the second half of phase III acceleration (S) was increased
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: T4: like T2, at the beginning of phase III, S was increased
Number of subjects: 18
Study: 9007796

Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Surgical Thrombectomy (ST)
Number of subjects: 37
Study: 1496125

Group type: EXPERIMENTAL
Intervention: Valproate treatment
Number of subjects: 12
Study: 6142463

Group type: EXPERIMENTAL
Intervention: 1.0 mg loprazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5.0 mg nitrazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30375339

Group type: EXPERIMENTAL
Intervention: BS/BS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: SJ/SJ
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: SJ/BS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BS
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: SJ
Number of subjects: 106
Study: 29111091

Group type: EXPERIMENTAL
Intervention: Incentive: 30% financial incentive on eligible fruits and vegetables purchased using food benefits
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Restriction: not allowed to buy sugar-sweetened beverages, sweet baked goods, or candies with food benefits
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Incentive plus Restriction
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control: no incentive/restriction
Number of subjects: 265
Study: 27280961

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 25831651

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 60
Study: 22575291

Group type: EXPERIMENTAL
Intervention: BMT and stent grafting of the proximal tear
Number of subjects: 61

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 61
Study: 22129214

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg once‐daily
Number of subjects: 8113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study: 18633041

Group type: EXPERIMENTAL
Intervention: RM group (n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RM-NIV group (n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NIV group (n = 25)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NIV groups on postoperative day 2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups on postoperative day 7
Number of subjects: 100
Study: 16194048

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea pressed juice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 40
Study: 12022239

Group type: EXPERIMENTAL
Intervention: Irbesartan (AT1 receptor antagonist)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Atenolol (beta1-adrenergic receptor blocker)
Number of subjects: 86
Study: 10639684

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7491227

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.1 mg/kg daily for 1 year)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1780618

Group type: COMPARATOR
Intervention: PGE2 administration for cervical maturation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin-induced maturation
Number of subjects: 0
Study: 7039244

Group type: EXPERIMENTAL
Intervention: Continuous heparin treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intermittent heparin treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both continuous and intermittent heparin treatment
Number of subjects: 28
Study: 30346226

Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard Treatment (TAU)
Number of subjects: 41
Study: 31475383

Group type: EXPERIMENTAL
Intervention: Intervention condition (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study: 27797925

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 26110815

Group type: EXPERIMENTAL
Intervention: %CDT
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: GGT
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: AST:ALT > 2
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: GGT, MCV, %CDT
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: MCV
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: AST, ALT, AST:ALT ratio
Number of subjects: 272
Study: 23134272

Group type: EXPERIMENTAL
Intervention: Music therapy and guided visual imagery
Number of subjects: 40
Study: 21294797

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 42
Study: 19901502

Group type: EXPERIMENTAL
Intervention: Tailored diabetic education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group diabetic education (control)
Number of subjects: 60
Study: 16675324

Group type: EXPERIMENTAL
Intervention: Beta-agonist asthma control scale derived from administrative data
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: Beta-agonist asthma control scale
Number of subjects: 2250
Study: 15327427

Group type: EXPERIMENTAL
Intervention: 3D SSFP imaging with slab-selective inversion prepulse
Number of subjects: 16

Group type: COMPARATOR
Intervention: SSFP without magnetization preparation
Number of subjects: 16

Group type: COMPARATOR
Intervention: SSFP with non-slab-selective inversion
Number of subjects: 16
Study: 10903238

Group type: EXPERIMENTAL
Intervention: Continuous group (maintenance prednisone dose for 6 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Demand group (withdrawn from prednisone at a rate of 5 mg per week)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Continuous group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Demand group
Number of subjects: 38
Study: 9138682

Group type: EXPERIMENTAL
Intervention: Spiradoline (U-62066E) 1.6 micrograms kg‐1, i.m.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Spiradoline (U-62066E) 4.0 micrograms kg‐1, i.m.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8161669

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day for 7 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3531309

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (b.i.d.)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at night
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 605
Study: 29730458

Group type: EXPERIMENTAL
Intervention: Bone‐anchored annular closure device (n=272 participants)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group (n=278 participants)
Number of subjects: 554
Study: 27895602

Group type: EXPERIMENTAL
Intervention: mBA + usual psychiatric rehabilitation
Number of subjects: 47

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 47
Study: 25915745

Group type: EXPERIMENTAL
Intervention: XpertMTB/RIF
Number of subjects: 4088

Group type: COMPARATOR
Intervention: Sputum smear examination
Number of subjects: 4088
Study: 23800717

Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 21742556

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg daily)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 19833454

Group type: EXPERIMENTAL
Intervention: sublingual 200microg misoprostol with 20UI intravenous oxytocin
Number of subjects: 250

Group type: COMPARATOR
Intervention: only oxytocin at the same dose
Number of subjects: 250
Study: 16706761

Group type: EXPERIMENTAL
Intervention: Hydrocolloid wound dressing (Avery H2460)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control treatment (Fucidine cream with Cutiplast sterile dressing)
Number of subjects: 16
Study: 15062699

Group type: EXPERIMENTAL
Intervention: Mini-incision technique for total hip arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional incision technique for total hip arthroplasty
Number of subjects: 0
Study: 11305006

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (5 g administered for 3 days)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 504
Study: 8994468

Group type: EXPERIMENTAL
Intervention: DPA ligated
Number of subjects: 34

Group type: COMPARATOR
Intervention: DPA preserved
Number of subjects: 34
Study: 7661144

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2% phosphoric acid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5% phosphoric acid
Number of subjects: 24
Study: 2767062

Group type: EXPERIMENTAL
Intervention: Submaximal treadmill walking at -20 degrees C for 8 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Submaximal treadmill walking at normal room temperature for 8 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Submaximal treadmill walking at 0 degrees C for 8 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Submaximal treadmill walking at -20 degrees C for 17 minutes
Number of subjects: 20
Study: 326237

Group type: EXPERIMENTAL
Intervention: 3% vancomycin gel applied topically using pre-trimmed plastic trays for 5 minutes every morning in school.
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (no vancomycin treatment).
Number of subjects: 268
Study: 30556275

Group type: EXPERIMENTAL
Intervention: Thermoplasticized gutta‐percha (E&Q system)
Number of subjects: 20

Group type: COMPARATOR
Intervention: GuttaFlow2
Number of subjects: 20
Study: 26559712

Group type: EXPERIMENTAL
Intervention: SMS (n = 147)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: E-mail (n = 149)
Number of subjects: 296
Study: 25809378

Group type: EXPERIMENTAL
Intervention: CJP (Criminal Justice Prompted)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Not CJP (Not Prompted by Criminal Justice)
Number of subjects: 434
Study: 24372884

Group type: EXPERIMENTAL
Intervention: Explicit speech and language therapy with visual support (Shape Coding)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waiting controls (no therapy during Phase 1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waiting controls (after receiving therapy in Phase 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined groups (therapy and waiting controls)
Number of subjects: 14
Study: 22289695

Group type: EXPERIMENTAL
Intervention: Resistance training intervention (24-week program)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 48
Study: 20134096

Group type: EXPERIMENTAL
Intervention: Shock wave (SW) therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18391039

Group type: EXPERIMENTAL
Intervention: Entecavir 1 mg daily dose in HIV- and HBV-coinfected patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entecavir 1 mg daily dose in HBV-monoinfected patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of entecavir pharmacokinetics between HIV- and HBV-coinfected and HBV-monoinfected patients
Number of subjects: 0
Study: 16570431

Group type: EXPERIMENTAL
Intervention: Acupuncture (early acupuncture group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with far infrared ray (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture after 7 days (group C)
Number of subjects: 0
Study: 12520628

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate/ethinyl estradiol tablets administered with a high-fat meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Norethindrone acetate/ethinyl estradiol tablets administered fasting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Norethindrone acetate/ethinyl estradiol tablets administered in solution
Number of subjects: 18
Study: 11221076

Group type: EXPERIMENTAL
Intervention: Shock waves alone (56 patients)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Shock waves and calcioantagonist (324 patients)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Calcioantagonist alone (101 patients)
Number of subjects: 481
Study: 9433680

Group type: EXPERIMENTAL
Intervention: Vitamins (beta‐carotene, 6 mg; vitamin C, 120 mg; and vitamin E, 15 mg)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Trace elements (zinc, 20 mg and selenium, 100 micrograms)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Trace elements associated with vitamins
Number of subjects: 756

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Mineral supplementation (trace elements)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Trace elements
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Vitamins
Number of subjects: 756
Study: 8270292

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Omeprazole 20 mg on alternate days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (single dose)
Number of subjects: 58
Study: 3304837

Group type: EXPERIMENTAL
Intervention: Ranitidine 200 mg/day iv
Number of subjects: 86

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/day iv
Number of subjects: 86
Study: 29863459

Group type: EXPERIMENTAL
Intervention: Early specialist vocational rehabilitation (VR) delivered by occupational therapists (OTs) in the community.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Early specialist vocational rehabilitation (VR)
Number of subjects: 78
Study: 27500175

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 105
Study: 24682207

Group type: EXPERIMENTAL
Intervention: Caffeine (2.9 mg/kg, equivalent to 200 mg or 2 espressos for a 70-kg adult)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 30
Study: 22075171

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 18668

Group type: COMPARATOR
Intervention: Control hepatitis A vaccine
Number of subjects: 18668
Study: 20088993

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study: 18177726

Group type: EXPERIMENTAL
Intervention: Taranabant (0.5, 2, 4, and 6 mg once per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16188812

Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf) at 200 mg/kg, repeated doses of 200, 100, and 100 mg/kg at 6-12 h intervals, maximum of four doses if OI deteriorated by >2 from baseline
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 61
Study: 14759108

Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture (IRO)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preprosthetic surgery to enlarge the denture‐bearing area (PPS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Construction of a new set of dentures (CD)
Number of subjects: 90
Study: 11068962

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8888089

Group type: EXPERIMENTAL
Intervention: Procardia XL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Adalat CC
Number of subjects: 15
Study: 10147473

Group type: EXPERIMENTAL
Intervention: Colfosceril palmitate (synthetic surfactant)
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 1237